Logo image of ALLO

ALLOGENE THERAPEUTICS INC (ALLO) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:ALLO - US0197701065 - Common Stock

1.335 USD
+0.1 (+8.54%)
Last: 11/24/2025, 3:27:06 PM
Fundamental Rating

3

Taking everything into account, ALLO scores 3 out of 10 in our fundamental rating. ALLO was compared to 533 industry peers in the Biotechnology industry. ALLO scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. ALLO is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ALLO has reported negative net income.
In the past year ALLO has reported a negative cash flow from operations.
ALLO had negative earnings in each of the past 5 years.
In the past 5 years ALLO always reported negative operating cash flow.
ALLO Yearly Net Income VS EBIT VS OCF VS FCFALLO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -100M -200M -300M

1.2 Ratios

With a Return On Assets value of -48.21%, ALLO perfoms like the industry average, outperforming 51.59% of the companies in the same industry.
ALLO has a Return On Equity (-67.24%) which is in line with its industry peers.
Industry RankSector Rank
ROA -48.21%
ROE -67.24%
ROIC N/A
ROA(3y)-46.19%
ROA(5y)-36.74%
ROE(3y)-58.29%
ROE(5y)-45.22%
ROIC(3y)N/A
ROIC(5y)N/A
ALLO Yearly ROA, ROE, ROICALLO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ALLO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ALLO Yearly Profit, Operating, Gross MarginsALLO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 -200K -400K -600K -800K -1M

More info and screens

6

2. Health

2.1 Basic Checks

ALLO does not have a ROIC to compare to the WACC, probably because it is not profitable.
ALLO has more shares outstanding than it did 1 year ago.
ALLO has more shares outstanding than it did 5 years ago.
There is no outstanding debt for ALLO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ALLO Yearly Shares OutstandingALLO Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M
ALLO Yearly Total Debt VS Total AssetsALLO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

Based on the Altman-Z score of -6.03, we must say that ALLO is in the distress zone and has some risk of bankruptcy.
ALLO has a Altman-Z score of -6.03. This is in the lower half of the industry: ALLO underperforms 63.23% of its industry peers.
ALLO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -6.03
ROIC/WACCN/A
WACC8.7%
ALLO Yearly LT Debt VS Equity VS FCFALLO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M 800M 1B

2.3 Liquidity

ALLO has a Current Ratio of 8.19. This indicates that ALLO is financially healthy and has no problem in meeting its short term obligations.
ALLO has a Current ratio of 8.19. This is in the better half of the industry: ALLO outperforms 75.61% of its industry peers.
A Quick Ratio of 8.19 indicates that ALLO has no problem at all paying its short term obligations.
ALLO's Quick ratio of 8.19 is fine compared to the rest of the industry. ALLO outperforms 75.61% of its industry peers.
Industry RankSector Rank
Current Ratio 8.19
Quick Ratio 8.19
ALLO Yearly Current Assets VS Current LiabilitesALLO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

More info and screens

4

3. Growth

3.1 Past

ALLO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 33.78%, which is quite impressive.
ALLO shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -100.00%.
Measured over the past years, ALLO shows a very negative growth in Revenue. The Revenue has been decreasing by -91.70% on average per year.
EPS 1Y (TTM)33.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%40.63%
Revenue 1Y (TTM)-100%
Revenue growth 3Y-91.7%
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, ALLO will show a quite strong growth in Earnings Per Share. The EPS will grow by 17.96% on average per year.
The Revenue is expected to grow by 475.53% on average over the next years. This is a very strong growth
EPS Next Y24.3%
EPS Next 2Y13.72%
EPS Next 3Y9.5%
EPS Next 5Y17.96%
Revenue Next Year-83.3%
Revenue Next 2Y-42.21%
Revenue Next 3Y681.16%
Revenue Next 5Y475.53%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
ALLO Yearly Revenue VS EstimatesALLO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
ALLO Yearly EPS VS EstimatesALLO Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4 6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ALLO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ALLO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALLO Price Earnings VS Forward Price EarningsALLO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALLO Per share dataALLO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y13.72%
EPS Next 3Y9.5%

More info and screens

0

5. Dividend

5.1 Amount

ALLO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ALLOGENE THERAPEUTICS INC

NASDAQ:ALLO (11/24/2025, 3:27:06 PM)

1.335

+0.1 (+8.54%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06 2025-11-06/amc
Earnings (Next)03-11 2026-03-11/amc
Inst Owners60.09%
Inst Owner Change-9.79%
Ins Owners6.94%
Ins Owner Change-0.13%
Market Cap296.21M
Revenue(TTM)N/A
Net Income(TTM)-212.01M
Analysts82
Price Target7.71 (477.53%)
Short Float %12.55%
Short Ratio6.86
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)17.05%
Min EPS beat(2)16.55%
Max EPS beat(2)17.55%
EPS beat(4)4
Avg EPS beat(4)14.25%
Min EPS beat(4)5.26%
Max EPS beat(4)17.64%
EPS beat(8)8
Avg EPS beat(8)9.76%
EPS beat(12)11
Avg EPS beat(12)9.95%
EPS beat(16)15
Avg EPS beat(16)10.24%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-1.18%
EPS NQ rev (1m)4.11%
EPS NQ rev (3m)-0.27%
EPS NY rev (1m)0%
EPS NY rev (3m)0.34%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)-100%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-9.99%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.94
P/tB 0.94
EV/EBITDA N/A
EPS(TTM)-0.98
EYN/A
EPS(NY)-0.94
Fwd EYN/A
FCF(TTM)-0.72
FCFYN/A
OCF(TTM)-0.71
OCFYN/A
SpS0
BVpS1.42
TBVpS1.42
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -48.21%
ROE -67.24%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-46.19%
ROA(5y)-36.74%
ROE(3y)-58.29%
ROE(5y)-45.22%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 5.13%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.19
Quick Ratio 8.19
Altman-Z -6.03
F-Score3
WACC8.7%
ROIC/WACCN/A
Cap/Depr(3y)17.35%
Cap/Depr(5y)225.27%
Cap/Sales(3y)2304.28%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)33.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%40.63%
EPS Next Y24.3%
EPS Next 2Y13.72%
EPS Next 3Y9.5%
EPS Next 5Y17.96%
Revenue 1Y (TTM)-100%
Revenue growth 3Y-91.7%
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-83.3%
Revenue Next 2Y-42.21%
Revenue Next 3Y681.16%
Revenue Next 5Y475.53%
EBIT growth 1Y56.01%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year21.77%
EBIT Next 3Y-2.08%
EBIT Next 5Y4.47%
FCF growth 1Y36.19%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y35.67%
OCF growth 3YN/A
OCF growth 5YN/A

ALLOGENE THERAPEUTICS INC / ALLO FAQ

What is the fundamental rating for ALLO stock?

ChartMill assigns a fundamental rating of 3 / 10 to ALLO.


What is the valuation status for ALLO stock?

ChartMill assigns a valuation rating of 0 / 10 to ALLOGENE THERAPEUTICS INC (ALLO). This can be considered as Overvalued.


What is the profitability of ALLO stock?

ALLOGENE THERAPEUTICS INC (ALLO) has a profitability rating of 1 / 10.


What is the financial health of ALLOGENE THERAPEUTICS INC (ALLO) stock?

The financial health rating of ALLOGENE THERAPEUTICS INC (ALLO) is 6 / 10.


What is the earnings growth outlook for ALLOGENE THERAPEUTICS INC?

The Earnings per Share (EPS) of ALLOGENE THERAPEUTICS INC (ALLO) is expected to grow by 24.3% in the next year.